Gilead Oncology Trodelvy Event Thanks | Gratitude for Your Participation | GileadPro

This website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the United Kingdom.

Oncology Prescribing Information

Gilead 2025 Oncology Exchange: Optimising Patient Care in TNBC

Sessions centred around various aspects of clinical practice and some of the meeting's key learnings included:

  • TNBC presents unique challenges compared with other BC subtypes, 1,2 and maximising patient HRQoL through proactive toxicity management and MDT care is imperative
  • Available ADCs have shown promising efficacy and a generally manageable safety profile in mTNBC* 3,4
  • Caring for patients with TNBC can have psychological impacts on healthcare professionals, and building emotional resilience through self-care is essential for mental wellbeing
  • Despite the challenges of TNBC, progress is being made in our understanding of the disease and the therapeutic options available, ultimately improving patient outcomes 8

Gilead 2025 Oncology Exchange: Optimising Patient Care in TNBC

Watch the highlights from the presentation delivered by Rachel Clifton.

The session covered AE management, improving HRQol and navigating challenging conversations with patients with mTNBC

Gilead 2025 Oncology Exchange: proactive toxicity management, optimising Trodelvy dosage and patient HRQoL

Watch the highlights from the presentations delivered by Dr Oikonomidou and Dr Fharat Raja.

Dr Oikonomidou's session covered the challenges and potential solutions to TNBC treatment sequencing. Dr Raja's explored proactive toxicity management, optimising Trodelvy dosage and patient HRQoL.

Abbreviations

ADC, antibody-drug conjugate; BC, breast cancer; HRQoL, health-related quality of life; MDT, multi-disciplinary team; mTNBC, (metastatic) triple-negative breast cancer

  • 1. Turkman YE, et al. Support Care Cancer. 2016;24(9):3715-21
  • 2. Kosmidis B, et al. ESMO 2019. Abstract 1835P
  • 3. Bardia A, et al. N Engl J Med. 2021;384(16):1529-41
  • 4. Modi S, et al. N Engl J Med. 2022;387(1):9-20
  • 5. Bardia A, et al. J Clin Oncol. 2024;42(19):2281-94
  • 6. Tsai M, et al. ESMO 2021. Abstract 259P
  • 7. Krop IE, et al. J Clin Oncol. 2023;41(36):5550-60
  • 8. Xiong N, et al. Front Oncol. 2024;14:1405491
.
Stay up to date

Receive email updates from Gilead, including promotional communications.

Register

June 2025 UKI-TRO-0276

Adverse events should be reported

Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.